Biotechnology · Telomere therapeutics
Rejuvenation Technologies
A Stanford spinout that switches telomerase on for a day or two with modified mRNA, then lets it fade. Nine NIH award records, one granted company patent, and no trial on any public registry as of September 2026.
Forty extra divisions
In a Stanford laboratory, human skin and muscle cells were given three doses of a modified messenger RNA over four days. The RNA carried the code for TERT, the working part of telomerase, the enzyme that rebuilds the protective caps on the ends of chromosomes.
Telomerase activity rose for 24 to 48 hours, then fell away. In that window the telomeres grew by up to 0.9 kilobases. The fibroblasts went on to divide about 28 more times than untreated cells. The muscle cells managed about 3.4 more.
What did not happen mattered more. The treated cells did not become immortal. Their telomeres began shortening again at the normal rate, and every treated population eventually stopped dividing and senesced like untreated cells.
“Now we have found a way to lengthen human telomeres by as much as 1,000 nucleotides, turning back the internal clock in these cells by the equivalent of many years of human life”, said Helen Blau, whose lab did the work, published in The FASEB Journal in May 2015.
It is the only peer-reviewed publication the company lists as its own.
Short telomeres are a real disease mechanism
The longevity framing can obscure a solid clinical fact. Short telomeres are the most common inherited cause of familial pulmonary fibrosis, and telomerase mutations appear in 2 to 5 percent of idiopathic cases and up to 15 percent of familial ones, per the company’s own NHLBI grant abstract. Median survival after diagnosis is under five years. In alcoholic hepatitis, the indication behind most of the federal money, mortality within a month of presentation runs at 25 to 50 percent.
The counterweight is cancer. In 2023 a Johns Hopkins team led by Mary Armanios described families carrying POT1 mutations whose telomeres were about 90 percent longer than their relatives. Fifteen of seventeen carriers had abnormal tissue growths, benign or malignant. The company’s answer is the transient design: its site states that “Temporary activation avoids the cancer risks associated with permanent telomerase activation.” That is a reasonable hypothesis. It has not been tested in a person in any trial that appears on a public registry.
Nineteen labs
John Ramunas was a fourth-year electrical engineering student in 1998 when he read that human telomeres had been artificially extended for the first time. He switched his major to biochemistry, then went looking for a lab that would turn it into a therapy.
“I interviewed at 19 telomere labs for my PhD before finding a lab willing to try to develop a telomere extension therapy, and that was Helen’s lab at Stanford. Helen loves overturning dogma”, he told Longevity.Technology in 2023.
He met Glenn Markov there. Both finished Stanford PhDs under Blau, who is a co-founder. Dan Chambers, a thoracic transplant physician at the University of Queensland, joined as chief medical officer in 2023. Y Combinator data dates the company to 2016 and places it in the Summer 2018 batch; the company’s patent counsel and a conference profile both date the launch to 2018.
Grants first, then a seed, then quiet
Federal agencies funded this company before venture capital did: NIAAA in September 2020, NHLBI for pulmonary fibrosis in 2022, NCATS and NIGMS in 2024, and in July 2026 a $2,063,303 NIAAA award meant to carry the liver program to an IND by June 2028.
The $10.6 million seed led by Khosla Ventures came in September 2023, with Shanda Ventures, Asymmetry Ventures, Merchant Adventures, Longevity Tech Fund and Y Combinator alongside. The company said then that it had $4.6 million in grants and $15.2 million in total, and that the money would take its programs to IND.
Three years later the YC listing says it is raising a $10 million extension with over $2 million wired, and gives team size as two.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| Founding science | The FASEB Journal, May 2015. Telomeres extended up to 0.9 kb in cultured human fibroblasts and myoblasts, adding 28 and 3.4 population doublings. Telomerase activity lasted 24 to 48 hours. Treated cells still senesced. Cultured cells only. | Public record |
| Animal data | Grant abstracts written by the company cite “highly successful rescue in mouse models of both pulmonary and liver fibrosis”. The founders say they have dosed rabbits and non-human primates too. None of it is published. | Company-stated |
| Mouse lifespan | The YC listing says the platform “Extends mouse lifespan by equivalent of 10 years in humans.” No supporting study was found in PubMed or elsewhere. | Not found |
| Company papers | A PubMed affiliation search for the company returns nothing. An author search for Ramunas J returns 12 records, the relevant one being the 2015 paper. | Public record |
| Independent work | A Hannover Medical School and Fraunhofer ITEM team reported in Aging Cell, November 2025, that hTERT modRNA lengthened telomeres and cut senescence and fibrosis markers in lung slices from end-stage fibrosis patients. Human tissue, not a human. | Independent |
| Registered trials | A ClinicalTrials.gov sponsor query on Sep 23, 2026 returns zero studies. The company site lists a Phase I of TeloAT2 in Australia, 24 participants over 12 months, liver and blood preclinical. No registry entry found. | Differs from the YC tagline |
| FDA record | No 510(k) or PMA, as expected for a drug. The claimed FDA INTERACT meeting is an informal pre-IND step the agency does not publish, so no record confirms or refutes it. No IND announced. | Company-stated |
| Patents | One granted US patent is assigned to the company, 12,721,818, dated Sep 1, 2026, on lung-preferential nanoparticles carrying TERT mRNA. The underlying TERT mRNA patents belong to Stanford. The claimed 50 or more grants would have to be mostly foreign. | Claim exceeds US record |
| Federal funding | Nine NIH award records under seven project numbers, FY2020 to FY2026, across NIAAA, NHLBI, NCATS and NIGMS, Ramunas the principal investigator on all. The amounts sum to $7,595,322. | Public record |
Read plainly: the cell biology is real, peer reviewed and now echoed by an unaffiliated German group. The animal results, the delivery platform and the safety case are company-stated and unpublished. “Entering clinical stage” is an intention, not a registration. This is not the Libella route, where a $1 million telomerase gene therapy was sold from a Colombian clinic in 2019 outside FDA oversight. One thread stays loose: the YC listing says the CEO is subject number one in a longevity trial, and no record of any such trial was found.
What to watch
- A trial registration, on the Australian registry for the stated Phase I or on ClinicalTrials.gov. Neither shows an entry today.
- Publication of the mouse and primate data. Nine NIH awards and no peer-reviewed company paper is an unusual ratio.
- The NIAAA award that began in July 2026, aimed at an IND for alcohol-associated liver damage by June 2028.
- Independent confirmation of the patent count and the mouse lifespan figure.
In their words
“I interviewed at 19 telomere labs for my PhD before finding a lab willing to try to develop a telomere extension therapy, and that was Helen’s lab at Stanford. Helen loves overturning dogma.”
John Ramunas, co-founder and CEO, Longevity.Technology, 2023 · Interview
“This is wrong and set back the field by decades. The reality is that permanent telomerase supports cancer, whereas healthy stem cells frequently turn on telomerase transiently throughout our lives to stave off the devastating effects of short telomeres.”
John Ramunas on the telomerase and cancer dogma, Longevity.Technology, 2023 · Interview
“Existing transient methods of extending telomeres act slowly, whereas our method acts over just a few days to reverse telomere shortening that occurs over more than a decade of normal aging.”
John Ramunas, Stanford Medicine news release, 2015 · University release
“A single dose of our telomerase mRNA reverses years of telomere shortening in hours.”
Glenn Markov, co-founder and COO, seed funding release, September 2023 · Company release
“Telomere extension in mice extends healthspan and lifespan, and there is a lot of evidence that it will work in humans as well. Our vision is to treat everyone, and we’re starting with fatal orphan diseases with high unmet medical need.”
John Ramunas, seed funding release, September 2023 · Company release
“Cells with very long telomeres accumulate mutations and appear to promote tumors and other types of growths that would otherwise be put in check by normal telomere shortening processes.”
Mary Armanios, Johns Hopkins University, NIH Research Matters, 2023 · Independent
“Humans and other large mammals exhibit very different telomere dynamics, however, so one can’t assume that the mouse data is a clear green signal.”
Reason, Fight Aging, September 2023 · Independent
“There’s a risk of activating a pre-cancerous cell that’s got all the alterations except telomerase, especially in people 65 and over.”
Jerry Shay, UT Southwestern, on a rival telomerase venture, MIT Technology Review, 2019 · Independent
Related companies
Sources
- Public recordTransient delivery of modified mRNA encoding TERT rapidly extends telomeres in human cells
- Public recordClinicalTrials.gov sponsor search, zero studies
- Public recordNIH RePORTER records for AA028749, HL166034, TR005328, GM153144 and AA033292
- Public recordUS patent 12,721,818 and applications naming John Ramunas
- Public recordSEC EDGAR full text search, Form D, zero hits
- IndependentTelomerase modRNA Offers a Novel RNA-Based Approach to Treat Human Pulmonary Fibrosis
- IndependentLong telomeres may heighten cancer risks
- InterviewTelomere-boosting mRNA therapeutic turns back the aging clock
- IndependentTurning Back the Clock With mRNA Telomerase Therapy
- IndependentTowards Targeted Telomerase Gene Therapy
- IndependentBuyer beware of this $1 million gene therapy for aging
- IndependentTelomere extension turns back aging clock in cultured human cells
- CompanyRejuvenation Technologies Raises $10.6M Seed Financing Led by Khosla Ventures
- CompanyCompany website, pipeline, team and publications pages
- CompanyY Combinator company listing
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
